Vitamin and mineral deficiencies are an underestimated risk of GLP-1 agonist treatments. The appetite reduction induced by tirzepatide can lead to significant nutritional deficits that are essential to detect and prevent. Mechanisms of deficiencies under GLP-1 agonists Tirzepatide reduces caloric intake by 25 to 40% on average (SURMOUNT-1, NEJM … Read more
Diarrhea and constipation are the most common digestive issues with tirzepatide. Here’s how to manage them daily. Bowel transit disorders are the second most frequent side effect with Mounjaro, after nausea. Approximately 16 to 23% of patients report episodes of diarrhea and 11 to 17% suffer from constipation. These two … Read more
Mounjaro isn’t a ‘magic shot’. Tirzepatide is a powerful tool, but it doesn’t replace motivation or lifestyle changes. Understanding how to maintain discipline beyond the pharmacological effect is essential for lasting results. The trap of ‘Mounjaro will do all the work’ The dramatic appetite reduction from tirzepatide … Read more
Fatphobia remains a major obstacle for patients on a weight loss journey. Individuals undergoing GLP-1 treatment face double stigmatization: that related to their weight and that related to the use of medication. Combating these discriminations is a public health issue. Fatphobia: a systemic discrimination The … Read more
Tirzepatide modifies the brain’s reward circuits involved in food addiction. This revolutionary discovery explains why many patients report a dramatic reduction in their compulsive cravings for food and even alcohol while on treatment. The Food Addiction Brain Food addiction shares neurobiological mechanisms with substance addictions. Ultra-processed foods … Read more
Eating disorders (EDs) represent a major area of concern under GLP-1 treatment. Tirzepatide profoundly alters the relationship with food, which can improve some EDs but also reveal or worsen others. EDs and obesity: a frequent comorbidity Binge eating disorder affects 20 to 30% of … Read more
The guilt of taking medication for weight loss affects a majority of patients on GLP-1 agonists. This shame, fueled by moralizing discourses on obesity, is a major obstacle to well-being and treatment adherence. It’s time to deconstruct it. Why guilt is so widespread A survey by the World Obesity Federation … Read more
The links between Mounjaro and mental health are under close scrutiny. While tirzepatide is not an antidepressant, the weight loss and hormonal changes it induces can have significant effects on mood and psychological well-being. Tirzepatide and neurotransmitters: what research shows GLP-1 and GIP receptors are … Read more
Body image is often out of sync with physical reality in patients on GLP-1. The mirror reflects a transformed body, but the mind retains the perception of the former body. This phenomenon, well-documented in psychology, requires particular attention during treatment. The disconnect between real body and mental image. Tirzepatide can cause a … Read more
Rapid weight loss with Mounjaro isn’t just about physical transformation. The psychological impact is profound and often underestimated: identity upheaval, disconnect between body and mental image, and reactions from those around you. Understanding these mechanisms is essential for a smooth journey. The psychological paradox of rapid weight loss Weight loss … Read more
The 10,000-step myth has been debunked by science, but moving more remains essential when taking GLP-1 agonists. Discover evidence-based physical activity goals and how to integrate movement into your daily life with tirzepatide. The 10,000-step myth: commercial origin The figure of 10,000 steps … Read more
Pelvic floor strengthening is a rarely discussed but essential exercise for obese patients, especially during weight loss with GLP-1 agonists. Urinary incontinence affects 60% of obese women and 30% of men, and it significantly improves with perineal rehabilitation. The pelvic floor: an overlooked muscle in … Read more